SCHEMBL5043478

SCHEMBL5043478

COc1cc(F)c(C(OC)C(=O)NCc2ccc(C(=N)NC(=O)OCc3ccccc3)cc2)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MASP2 O00187 4/20 0.47
PKM P14618 1/20 0.42
CYP3A4 P08684 5/20 0.41
TSHR P16473 2/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 3/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
CTSD P07339 1/20 0.40
CASP1 P29466 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
KMT2A Q03164 1/20 0.40
GAA P10253 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5041100 0.87 MASP2 (0.43) MASP2CYP3A4LMNAALDH1A1CTSD
SCHEMBL5043460 0.85 MASP2 (0.42) MASP2CYP3A4TSHRLMNAALDH1A1
SCHEMBL5037437 0.84 NPC1 (0.38) MASP2PKMLMNAALDH1A1MAPT
SCHEMBL5037329 0.84 MASP2 (0.47) MASP2CYP3A4TSHRLMNAALDH1A1
SCHEMBL5045462 0.83 F10 (0.44) MASP2CYP3A4TSHRLMNAALDH1A1
SCHEMBL5043474 0.82 PLAU (0.43) PKMCYP3A4TSHRLMNAALDH1A1
SCHEMBL5043469 0.82 PLAU (0.43) PKMCYP3A4TSHRLMNAALDH1A1
SCHEMBL5041146 0.81 F2 (0.48) MASP2PKMALDH1A1
SCHEMBL5041447 0.81 F2 (0.48) MASP2PKMALDH1A1
SCHEMBL5043621 0.81 F2 (0.48) MASP2PKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US claimed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US claimed
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 MASP2 370/4885PKM 4225/4885CYP3A4 1458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.